{
  "docId": "019de076-e0bc-7319-b2fa-5eeb46bcf895",
  "docSlug": "439c1d555948cf75a9b0a41f96565740",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 29,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a timeline-based process flow to illustrate the clinical trial structure.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-e0bc-7319-b2fa-5eeb46bcf895/16",
  "deckHref": "/decks/019de076-e0bc-7319-b2fa-5eeb46bcf895",
  "deckJsonHref": "/decks/019de076-e0bc-7319-b2fa-5eeb46bcf895.json",
  "deckAnchorHref": "/decks/019de076-e0bc-7319-b2fa-5eeb46bcf895#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.9,
        "x": 0.05,
        "y": 0.325
      },
      "kind": "diagram",
      "text": "Trial design flow showing IV LAMB initial treatment, 2:1 randomization, and split into Experimental (MAT2203) and Comparator (IV LAMB + SoC) arms over 12 weeks.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3bd0e12f-90cd-40c4-93d7-dc6c3f8ae22b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.14
      },
      "kind": "list",
      "text": "To demonstrate that initial treatment with IV LAMB followed by step-down to oral MAT2203 is comparable to (noninferior) SoC treatment in adult patients with Invasive Aspergillosis (IA) who are unable to receive treatment with a mold-active azole and have limited alternative treatment options\nPatients will be randomized 2:1 to receive either oral MAT2203 (Experimental Arm) or continued IV LAMB followed by Standard of Care (Comparator Arm)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a7907a2-d70c-4463-9f8f-3edc6b30265d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.96,
        "x": 0.02,
        "y": 0.7
      },
      "kind": "table",
      "text": "Primary and secondary endpoints and patient inclusion criteria.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c5e5885a-6e62-4360-b594-3b7071b06aa7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "FDA-Agreed Phase 3 Study Design in Invasive Aspergillosis (IA) (the “ORALTO” Trial)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07f0def9-9e00-4d66-8d14-16d4411d9a6e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "e425fc9d-e798-4b32-9cbc-b6191800db9b",
      "evidence": "Timeline-based representation of clinical trial phases and treatment duration.",
      "confidence": 0.7
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}